The predictive role of the TAPSE/sPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension

Marco de Pinto, Francesca Coppi, Amelia Spinella, Gianluca Pagnoni, Vernizia Morgante, Pierluca Macripò, Matteo Boschini, Anna Francesca Guerra, Francesca Tampieri, O. Secchi, Martina Orlandi, G. Amati, Federica Lumetti, Gilda Sandri, Rosario Rossi, Giuseppe Boriani, Anna Vittoria Mattioli, Clodoveo Ferri, Dilia GiuggioliFrontiers in Cardiovascular Medicine 2024 · DOI

TL;DR

This study investigates the prognostic value of the TAPSE/sPAP ratio in patients with systemic sclerosis (SSc) and pulmonary hypertension (PH). The findings confirm that a low TAPSE/sPAP ratio is a significant independent predictor of mortality and cardiovascular events in this patient population, highlighting its importance in risk stratification.

What Problem Does This Paper Address?

Systemic sclerosis (SSc) is a complex autoimmune disease that can affect multiple organs, with pulmonary hypertension (PH) being a major contributor to morbidity and mortality. Accurately predicting which SSc patients with PH are at highest risk for adverse outcomes (like death or cardiovascular events) is crucial for timely intervention and improved patient management. While the TAPSE/sPAP ratio (a measure of right ventricle-pulmonary artery coupling) has emerged as a useful prognostic marker in general PH populations, its specific role in SSc-associated PH, particularly when complicated by interstitial lung disease (ILD), has been less explored. This paper aims to fill that gap by evaluating the predictive power of this ratio in a cohort of SSc patients with PH.

Methods

This was a retrospective, single-center study. The researchers analyzed data from 61 SSc patients with PH who were referred to their Scleroderma Unit between October 2013 and October 2023. All patients underwent comprehensive clinical evaluations, routine blood tests, and functional/instrumental assessments, including right heart catheterization (RHC) to confirm PH diagnosis and classification. Key measurements included the TAPSE/sPAP ratio, pulmonary vascular resistance (PVR), and various clinical parameters. Statistical analyses involved univariate and multivariate Cox regression to identify independent predictors of mortality and cardiovascular events, as well as Kaplan-Meier curves to assess survival.

Datasets

The study utilized data from a cohort of 61 SSc patients with PH. This is a single-center cohort, and no new public datasets were introduced.

Key Insights and Ideas

  • TAPSE/sPAP as a Key Indicator: The study strongly reinforces the TAPSE/sPAP ratio as a critical, non-invasive marker for predicting poor outcomes in SSc patients with PH. A low ratio signals a disconnect between the right ventricle's pumping ability and the pressure it faces in the pulmonary arteries.
  • SSc-PH with ILD is High Risk: Patients with SSc and PH complicated by significant interstitial lung disease (SSc-PH) showed worse survival rates and a higher incidence of cardiovascular events compared to those with SSc-PAH (pulmonary arterial hypertension). This highlights the complex interplay of lung and heart issues in this subgroup.
  • Beyond the Ratio: While the TAPSE/sPAP ratio was a standout predictor, other factors like male gender and the presence of significant ILD also emerged as independent predictors of mortality and cardiovascular events, underscoring a multifactorial risk profile.
  • Therapeutic Considerations: The study noted the use of PAH-specific therapies in SSc-PH patients with ILD, even when not strictly indicated by current guidelines, suggesting a potential unmet need and the complexity of managing these patients.

Key Results

  • Mortality and Events: During the follow-up period, 60.1% of patients experienced at least one cardiovascular event, and 62% died. The primary causes of death were PH (39.4%) and other heart-related events (39.4%).
  • TAPSE/sPAP and Mortality: Deceased patients had a significantly lower TAPSE/sPAP ratio (0.3 ± 0.12 mm/mmHg) compared to survivors (0.48 ± 0.17 mm/mmHg, p < 0.001).
  • Independent Predictors: In multivariate analysis, a TAPSE/sPAP ratio <0.32 mm/mmHg, male gender, and the presence of significant ILD were identified as independent predictors of both mortality and cardiovascular events.
  • SSc-PAH vs. SSc-PH: Patients with SSc-PH had lower survival rates (25 months) compared to SSc-PAH patients (55.3 months, p = 0.05).

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: The study's retrospective nature means it cannot establish causality definitively.
  • Small Cohort Size: While well-characterized, the cohort size is relatively small, which can limit the generalizability of findings.
  • Monocentric Study: Data comes from a single center, which might introduce selection bias.
  • Interobserver Agreement: The potential for variability in echocardiographic measurements due to interobserver agreement is noted, although standardized protocols were used.
  • Unavailability of Certain Parameters: Detailed assessments of left ventricular diastolic function and left atrial volume were not consistently available.

Future work could involve larger, prospective, multi-center studies to further validate these findings. Investigating the precise relationship between microangiopathic cardiomyopathy, RV-PA coupling, and PH in SSc, especially with significant lung fibrosis, is also recommended. Clarifying the role and optimal use of PAH-specific therapies in SSc patients with ILD warrants further research, potentially through randomized controlled trials.

Summary updated

Abstract

Our work confirmed the predictive role of the TAPSE/sPAP ratio for mortality and cardiovascular events in patients with SSc complicated by PH.
BibTeX
@inproceedings{pinto2024predictive,
  author = {Marco de Pinto and Francesca Coppi and Amelia Spinella and Gianluca Pagnoni and Vernizia Morgante and Pierluca Macripò and Matteo Boschini and Anna Francesca Guerra and Francesca Tampieri and O. Secchi and Martina Orlandi and G. Amati and Federica Lumetti and Gilda Sandri and Rosario Rossi and Giuseppe Boriani and Anna Vittoria Mattioli and Clodoveo Ferri and Dilia Giuggioli},
  title = {{The predictive role of the TAPSE/sPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2024},
  doi = {10.3389/fcvm.2024.1430903},
}
Figure